Ajax Therapeutics, Inc.

Ajax Therapeutics, Inc. is a biopharmaceutical company pursuing selective Type II JAK2 inhibitors for myeloproliferative neoplasms (MPNs) like myelofibrosis and polycythemia vera. Lead program AJ1-11095 is in Phase 1 trials (AJX-101/NCT06343805) for patients previously treated with Type I JAK2 inhibitors.